Journal
MOLECULAR PHARMACOLOGY
Volume 75, Issue 6, Pages 1249-1261Publisher
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/mol.108.053140
Keywords
-
Categories
Funding
- National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [DK070787]
- National Institutes of Health National Institute of General Medicine [GM051366]
- Vanderbilt-Ingram Cancer Center [CA68485]
- Center for Molecular Neuroscience [MH19732]
- Vanderbilt Diabetes Research and Training Center [DK20593]
Ask authors/readers for more resources
With the recent clinical success of drugs targeting protein kinase activity, drug discovery efforts are focusing on the role of reversible protein phosphorylation in disease states. The activity of protein phosphatases, enzymes that oppose protein kinases, can also be manipulated to alter cellular signaling for therapeutic benefits. In this review, we present protein serine/threonine phosphatases as viable therapeutic targets, discussing past successes, current challenges, and future strategies for modulating phosphatase activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available